Posted by Michael Wonder on 27 Jan 2026
Eisai submits marketing authorisation variation to EMA for intravenous maintenance dosing every four weeks with Leqembi (lecanemab)
26 January 2026 - BioArctic AB's partner Eisai announced today that they have submitted a proposed marketing authorisation variation to the EMA for a once every four weeks intravenous infusion maintenance dosing for lecanemab.
In the EU, lecanemab is indicated for the treatment of patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early Alzheimer's disease) who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.
